

Amin Polzin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5215856/publications.pdf>

Version: 2024-02-01

54
papers

644
citations

623734

14
h-index

642732

23
g-index

54
all docs

54
docs citations

54
times ranked

1007
citing authors

#	ARTICLE	IF	CITATIONS
1	European NSTEMI guidelinesâ€”return of clopidogrel?. European Journal of Clinical Pharmacology, 2022, 78, 151-153.	1.9	1
2	Safety of transoesophageal echocardiography during structural heart disease interventions under procedural sedation: a single-centre study. European Heart Journal Cardiovascular Imaging, 2022, 24, 68-77.	1.2	7
3	Days alive and out of hospital after left ventricular assist device implantation. ESC Heart Failure, 2022, 9, 2455-2463.	3.1	5
4	Early restenosis of a direct flow transcatheter aortic valve prosthesis. Catheterization and Cardiovascular Interventions, 2021, 97, E716-E718.	1.7	0
5	Noncanonical Effects of Oral Thrombin and Factor Xa Inhibitors in Platelet Activation and Arterial Thrombosis. Thrombosis and Haemostasis, 2021, 121, 122-130.	3.4	8
6	Aortic valve calcification is subject to aortic stenosis severity and the underlying flow pattern. Heart and Vessels, 2021, 36, 242-251.	1.2	10
7	Risk modeling in transcatheter aortic valve replacement remains unsolved: an external validation study in 2946 German patients. Clinical Research in Cardiology, 2021, 110, 368-376.	3.3	12
8	Risk prediction of bleeding and MACCE by PRECISE-DAPT score post-PCI. IJC Heart and Vasculature, 2021, 33, 100750.	1.1	5
9	Predictors of calcification distribution in severe tricuspid aortic valve stenosis. International Journal of Cardiovascular Imaging, 2021, 37, 2791-2799.	1.5	3
10	Computed tomography derived predictors of permanent pacemaker implantation after transcatheter aortic valve replacement: A metaâ€”analysis. Catheterization and Cardiovascular Interventions, 2021, 98, E897-E907.	1.7	8
11	Factors associated with a high or low implantation of self-expanding devices in TAVR. Clinical Research in Cardiology, 2021, 110, 1930-1938.	3.3	3
12	Aspirin I.V. Loading during Elective Percutaneous Coronary Intervention. Pharmacology, 2021, 106, 682-686.	2.2	1
13	Short- and Mid-Term Outcomes in Patients Deemed Inoperable Undergoing Transapical and Transfemoral TAVR with an STS-PROM below Four Percent. Journal of Clinical Medicine, 2021, 10, 2993.	2.4	1
14	Risk Factors for Acute Kidney Injury Requiring Renal Replacement Therapy after Orthotopic Heart Transplantation in Patients with Preserved Renal Function. Journal of Clinical Medicine, 2021, 10, 4117.	2.4	1
15	Impact of high on-treatment platelet reactivity after angioplasty in patients with critical limb ischemia. Vascular Pharmacology, 2021, 141, 106925.	2.1	1
16	Life impact of VAâ€”ECMO due to primary graft dysfunction in patients after orthotopic heart transplantation. ESC Heart Failure, 2021, , .	3.1	9
17	Excess Mortality in Aspirin and Dipyron (Metamizole) Coâ€”Medicated in Patients With Cardiovascular Disease: A Nationwide Study. Journal of the American Heart Association, 2021, 10, e022299.	3.7	3
18	MTX Treatment Does Not Improve Outcome in Mice with AMI. Pharmacology, 2021, 106, 225-232.	2.2	3

#	ARTICLE	IF	CITATIONS
19	Kidney function stratified outcomes of percutaneous left atrial appendage occlusion in patients with atrial fibrillation and high bleeding risk. <i>Acta Cardiologica</i> , 2020, 75, 312-320.	0.9	13
20	Enhanced Platelet Reactivity under Aspirin Medication and Major Adverse Cardiac and Cerebrovascular Events in Patients with Coronary Artery Disease. <i>Pharmacology</i> , 2020, 105, 118-122.	2.2	7
21	Navigating the “Optimal Implantation Depth” With a Self-Expandable TAVR Device—Daily Clinical Practice. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 679-688.	2.9	44
22	Antithrombotic therapy for chronic coronary syndrome and atrial fibrillation: less might be more. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 321-324.	2.1	3
23	Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1. <i>Circulation Research</i> , 2020, 126, 486-500.	4.5	87
24	Duplex echocardiography in multivalvular heart disease after percutaneous mitral valve repair?. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13340.	3.4	0
25	Impact of Combined “CHADS-BLED” Score to Predict Short-Term Outcomes in Transfemoral and Transapical Aortic Valve Replacement. <i>Journal of Interventional Cardiology</i> , 2020, 2020, 1-9.	1.2	2
26	Response by Petzold et al to Letter Regarding Article, “Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1”. <i>Circulation Research</i> , 2020, 126, e116-e117.	4.5	2
27	Current and Future Aspects of Multimodal Imaging, Diagnostic, and Treatment Strategies in Bicuspid Aortic Valve and Associated Aortopathies. <i>Journal of Clinical Medicine</i> , 2020, 9, 662.	2.4	1
28	Response by Petzold et al to Letter Regarding Article, “Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1”. <i>Circulation Research</i> , 2020, 126, e54-e55.	4.5	1
29	Novel insights on outcome in horizontal aorta with self-expandable new-generation transcatheter aortic valve replacement devices. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1511-1519.	1.7	13
30	New insights on potential permanent pacemaker predictors in TAVR using the largest self-expandable device. <i>Cardiovascular Diagnosis and Therapy</i> , 2020, 10, 1816-1826.	1.7	6
31	Prediction of One-Year Mortality Based upon A New Staged Mortality Risk Model in Patients with Aortic Stenosis Undergoing Transcatheter Valve Replacement. <i>Journal of Clinical Medicine</i> , 2019, 8, 1642.	2.4	1
32	Micro-dislodgement during transcatheter aortic valve implantation with a contemporary self-expandable prosthesis. <i>PLoS ONE</i> , 2019, 14, e0224815.	2.5	8
33	Oral Anticoagulation Therapy and Progression of Calcific Aortic Valve Stenosis: Factor Xa versus Factor IIa Inhibition?. <i>Pharmacology</i> , 2019, 104, 212-214.	2.2	2
34	Cardioprotection by very mild hypothermia in mice. <i>Cardiovascular Diagnosis and Therapy</i> , 2019, 9, 64-67.	1.7	4
35	Platelet Reactivity in Patients on Aspirin and Clopidogrel Therapy Measured by a New Bedside Whole-Blood Assay. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 73, 40-47.	1.9	14
36	Cost-comparison of third generation transcatheter aortic valve implantation (TAVI) devices in the German Health Care System. <i>International Journal of Cardiology</i> , 2019, 278, 40-45.	1.7	8

#	ARTICLE	IF	CITATIONS
37	Malondialdehyde Assay in the Evaluation of Aspirin Antiplatelet Effects. <i>Pharmacology</i> , 2019, 103, 23-29.	2.2	3
38	Antiplatelet effects of aspirin and clopidogrel after left atrial appendage (LAA) occluder implantation. <i>International Journal of Cardiology</i> , 2019, 275, 95-100.	1.7	5
39	Dose reduction, oral application, and order of intake to preserve aspirin antiplatelet effects in dipyron co-medicated chronic artery disease patients. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 13-20.	1.9	12
40	Patent foramen ovale closure or medical therapy for cryptogenic ischemic stroke: an updated meta-analysis of randomized controlled trials. <i>Clinical Research in Cardiology</i> , 2018, 107, 745-755.	3.3	15
41	Perioperative aspirin therapy in non-cardiac surgery: A systematic review and meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2018, 258, 59-67.	1.7	14
42	Aspirin Inhibits Platelet-Derived Sphingosine-1-Phosphate Induced Endothelial Cell Migration. <i>Pharmacology</i> , 2018, 101, 72-75.	2.2	4
43	The Latest Evolution of the MedtronicÂCoreValve System in the Era of Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 2314-2322.	2.9	60
44	Current and future aspects of multimodal and fusion imaging in structural and coronary heart disease. <i>Clinical Research in Cardiology</i> , 2018, 107, 49-54.	3.3	22
45	Dynamic coronary roadmapping during percutaneous coronary intervention: a feasibility study. <i>European Journal of Medical Research</i> , 2018, 23, 36.	2.2	22
46	Analgesic medication with dipyron in patients with coronary artery disease: Relation to MACCE. <i>International Journal of Cardiology</i> , 2017, 236, 76-81.	1.7	22
47	Thromboxane Formation Assay to Identify High On-Treatment Platelet Reactivity to Aspirin. <i>Pharmacology</i> , 2017, 100, 127-130.	2.2	6
48	Cardiovascular Magnetic Resonance Relaxometry Predicts Regional Functional Outcome After Experimental Myocardial Infarction. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	2.6	16
49	Prevention of dipyron (metamizole) induced inhibition of aspirin antiplatelet effects. <i>Thrombosis and Haemostasis</i> , 2015, 114, 87-95.	3.4	25
50	High on-treatment platelet reactivity in transcatheter aortic valve implantation patients. <i>European Journal of Pharmacology</i> , 2015, 751, 24-27.	3.5	37
51	Impaired clopidogrel antiplatelet effects and age: Young patients at risk. <i>International Journal of Cardiology</i> , 2015, 187, 216-218.	1.7	6
52	Impairment of aspirin antiplatelet effects by non-opioid analgesic medication. <i>World Journal of Cardiology</i> , 2015, 7, 383.	1.5	17
53	Aspirin inhibits release of platelet-derived sphingosine-1-phosphate in acute myocardial infarction. <i>International Journal of Cardiology</i> , 2013, 170, e23-e24.	1.7	18
54	Dipyron (Metamizole) Can Nullify theÂAntiplateletÂEffect of Aspirin in PatientsÂWithÂCoronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1725-1726.	2.8	43